Customize your JAMA Network experience by selecting one or more topics from the list below.
Hypertrophic cardiomyopathy (HCM) has fascinated (and scared) cardiologists for years owing, in part, to the relatively few cases most physicians will see in their practice, coupled with increased risk for sudden death, complex yet incomplete genetic understanding, and enigmatic hemodynamics. The management of symptomatic patients with HCM evolved over the past (nearly) 6 decades owing to focused efforts to understand the pathophysiology and perfect the necessary skills to delivery exemplary outcomes.1 We have learned that it is entirely possible for patients with HCM to have excellent quality of life and normal lifespans, that most patients can be treated with pharmacologic therapy, and that for most patients who remain symptomatic, there are procedures that can deliver excellent benefit with low risk.
Ommen SR, Nishimura RA. Hypertrophic Cardiomyopathy—One Case per Year? A Clarion Call to Do What Is Right. JAMA Cardiol. 2016;1(3):333–334. doi:10.1001/jamacardio.2016.0277
Create a personal account or sign in to: